Bastide Le Confort Medical


Target price cut by 3%

20/10/21 -"We have integrated (partly) the actual FY20/21 figures. Despite stronger revenue, the net result was lower-than-expected due to a weaker margin and larger exceptional expenses. For FY21/22, we ..."

Pages
49
Language
English
Published on
20/10/21
You may also be interested by these reports :
06/05/24
Demant’s Q1 sales missed the company-compiled consensus. The low-single-digit growth was led by positive contributions from Hearing Aids and ...

02/05/24
GN’s Q1 profitability beat the street’s expectations, despite sales being largely in line. The mid-single digit growth was led by Hearing, while ...

01/05/24
Drägerwerk reported Q1 24 numbers which were bang in-line with the prelims. Sales were down with the expected segmental trends. However, with a ...

30/04/24
The drop in our DCF valuation is largely a reflection of the double digit earnings cut for the next two forecast years, as we re-phase the delivery ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO